Trump rx tirzepatide?

Do you mean “tirzepatide” in general, or are you asking about whether a specific person (like Donald Trump) has a prescription for it? I can’t share or verify private medical information about individuals, but I’m happy to give you a concise overview of tirzepatide and how it’s used.

What tirzepatide is
- A once-weekly injectable medication that activates two receptors (GLP-1 and GIP).
- Brand names: Mounjaro (for type 2 diabetes) and Zepbound (weight management).

What it’s used for
- Type 2 diabetes in adults (to improve glycemic control, usually with diet and exercise).
- Chronic weight management in adults with BMI >= 27 with at least one weight-related condition, or BMI >= 30.

How it’s prescribed (typical dosing)
- Start with a low dose and gradually increase:
- For diabetes (Mounjaro): start 2.5 mg once weekly for 4 weeks, then may increase to 5 mg, then 10 mg, then 15 mg once weekly (maximum 15 mg).
- For weight management (Zepbound): similar escalating schedule (2.5 mg → 5 mg → 10 mg → 15 mg weekly as tolerated).
- Given by subcutaneous injection once weekly in the abdomen, thigh, or upper arm.
- Dosing plan is tailored by your clinician based on response and tolerability.

What to know about safety and side effects
- Common: nausea, vomiting, diarrhea, decreased appetite, constipation, injection-site reactions.
- May cause low blood sugar if used with insulin or certain diabetes pills.
- Rare but serious: pancreatitis, gallbladder problems, and potential thyroid C-cell tumors (noted in animal studies; human risk not fully established). Not recommended in people with a personal or family history of medullary thyroid carcinoma or MEN2.
- Pregnancy is not advised with tirzepatide; use effective contraception.
- Caution with other meds that require precise timing for absorption (tirzepatide slows gastric emptying).

Cost and access
- It can be expensive; many plans cover it for approved indications. Patient support programs may help with access.

Would you like:
- A quick side-by-side comparison with another GLP-1/GIP drug (e.g., semaglutide)?
- A brief dosing chart you can show a clinician?
- More detail on which conditions are approved and typical timelines for response?